Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib food effect and formulation study in healthy volunteers
NCT04748926Phase 1Completed
- Sponsor
- Sanofi
- Start
- Apr 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rilzabrutinib (2 arms), sponsored by Sanofi. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 3 more. Started Apr 2021; status: completed.
02
Drugs
rilzabrutinib
Beyond the preview
Go deeper on NCT04748926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04748926.